Latest Period
Q4 2025
Security Snapshot
AGIOS PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (AGIO) Institutional Ownership
CUSIP: 00847X104
13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026
Institutions Reporting
236
Shares (Excl. Options)
61,265,068
Price
$27.22
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- AGIO on Nasdaq
- Shares outstanding
- 59,097,039
- Price per share
- $35.11
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 61,265,068
- Total reported value
- $1,667,804,535
- % of total 13F portfolios
- 0%
- Share change
- -4,066,017
- Value change
- -$303,115,539
- Number of holders
- 236
- Price from insider filings
- $35.11
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- AGIO - AGIOS PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share is tracked under CUSIP 00847X104.
- 236 institutions reported positions in Q4 2025.
- 7 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 236 to 103 between Q4 2025 and Q1 2026.
- Reported value moved from $1,667,804,535 to $588,225,683.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 236 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 00847X104?
CUSIP 00847X104 identifies AGIO - AGIOS PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00847X104:
Significant Owners of AGIOS PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (AGIO) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Farallon Capital Partners, L.P. | 8.8% | -11% | $146,117,182 | -$14,583,696 | 5,159,505 | -9.1% | Dapice Joshua J. | 31 Dec 2025 |
| BlackRock, Inc. | 7.8% | $150,100,362 | 4,513,170 | BlackRock, Inc. | 30 Jun 2025 | |||
| STATE STREET CORP | 5.3% | $88,022,666 | 3,108,145 | STATE STREET CORPORATION | 31 Dec 2025 | |||
| VANGUARD CAPITAL MANAGEMENT LLC | 5.3% | $104,472,757 | 3,088,169 | Vanguard Capital Management | 31 Mar 2026 | |||
| ARMISTICE CAPITAL, LLC | 5.2% | $85,979,520 | 3,036,000 | Armistice Capital, LLC | 31 Dec 2025 | |||
| Lynx1 Capital Management LP | 5.1% | $105,819,749 | 3,013,949 | Lynx1 Capital Management LP | 29 Apr 2026 | |||
| Paradigm Biocapital Advisors LP | 4.9% | -6% | $115,344,498 | -$6,198,499 | 2,873,555 | -5.1% | Paradigm BioCapital Advisors LP | 30 Sep 2025 |
As of 31 Dec 2025, 236 institutional investors reported holding 61,265,068 shares of AGIOS PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (AGIO). This represents 104% of the company’s total 59,097,039 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of AGIOS PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (AGIO) together control 78% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| VANGUARD GROUP INC | 9.5% | 5,594,353 | -0.19% | 0% | $152,278,288 |
| BlackRock, Inc. | 8.9% | 5,235,429 | +15% | 0% | $142,508,377 |
| FARALLON CAPITAL MANAGEMENT LLC | 8.7% | 5,159,505 | -11% | 0.81% | $140,441,726 |
| STATE STREET CORP | 5.3% | 3,108,145 | +37% | 0% | $84,603,707 |
| ARMISTICE CAPITAL, LLC | 5.1% | 3,036,000 | +297% | 2% | $82,639,920 |
| Erste Asset Management GmbH | 4.7% | 2,804,900 | +1.4% | 0.64% | $76,343,084 |
| D. E. Shaw & Co., Inc. | 3.1% | 1,837,186 | +400% | 0.04% | $50,008,203 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 2.9% | 1,701,409 | 0% | 0.07% | $46,312,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 1,413,538 | -0.2% | 0% | $38,483,546 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 2.3% | 1,360,730 | +38% | 0.04% | $37,039,000 |
| CITADEL ADVISORS LLC | 2.3% | 1,348,968 | +174% | 0.02% | $36,718,909 |
| MPM BIOIMPACT LLC | 2.2% | 1,303,373 | 4.1% | $35,477,813 | |
| Frazier Life Sciences Management, L.P. | 2.2% | 1,279,754 | 0% | 0.94% | $34,834,904 |
| GW&K Investment Management, LLC | 2% | 1,207,301 | +42% | 0.28% | $32,863,000 |
| TCG Crossover Management, LLC | 2% | 1,181,841 | -17% | 1.1% | $32,169,712 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.9% | 1,142,432 | 0.04% | $31,096,999 | |
| JANE STREET GROUP, LLC | 1.9% | 1,121,050 | +184% | 0.04% | $30,514,981 |
| GOLDMAN SACHS GROUP INC | 1.7% | 1,033,974 | +28% | 0% | $28,144,772 |
| DIMENSIONAL FUND ADVISORS LP | 1.7% | 1,004,341 | -1.7% | 0.01% | $27,338,360 |
| MORGAN STANLEY | 1.5% | 894,036 | +114% | 0% | $24,335,668 |
| Rock Springs Capital Management LP | 1.4% | 799,163 | -17% | 1.1% | $21,753,217 |
| Capital International Investors | 1.2% | 703,865 | 0% | $19,159,205 | |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.1% | 637,886 | -62% | 0% | $17,364,000 |
| Balyasny Asset Management L.P. | 1.1% | 635,069 | +28% | 0.03% | $17,286,578 |
| SCS Capital Management LLC | 1% | 598,765 | 0% | 0.17% | $16,298,383 |
Institutional Holders of AGIOS PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (AGIO) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 17,741,005 | $588,225,683 | +$71,729,478 | $33.83 | 103 |
| 2025 Q4 | 61,265,068 | $1,667,804,535 | -$303,115,539 | $27.22 | 236 |
| 2025 Q3 | 63,487,439 | $2,545,616,686 | +$81,769,351 | $40.14 | 216 |
| 2025 Q2 | 61,683,672 | $2,051,725,997 | +$65,237,829 | $33.26 | 211 |
| 2025 Q1 | 59,963,279 | $1,757,322,194 | -$10,187,060 | $29.30 | 216 |
| 2024 Q4 | 59,832,436 | $1,966,429,716 | +$37,958,970 | $32.86 | 221 |
| 2024 Q3 | 58,096,571 | $2,582,267,784 | -$8,181,474 | $44.43 | 204 |
| 2024 Q2 | 58,132,966 | $2,506,935,894 | -$125,225,015 | $43.12 | 203 |
| 2024 Q1 | 61,946,791 | $1,811,267,450 | +$89,235,062 | $29.24 | 183 |
| 2023 Q4 | 59,884,422 | $1,333,701,271 | +$15,853,345 | $22.27 | 167 |
| 2023 Q3 | 59,110,077 | $1,463,036,585 | -$8,921,651 | $24.75 | 142 |
| 2023 Q2 | 59,366,269 | $1,679,785,246 | +$16,420,594 | $28.32 | 150 |
| 2023 Q1 | 58,996,438 | $1,355,139,176 | -$9,985,145 | $22.97 | 161 |
| 2022 Q4 | 59,442,573 | $1,669,125,079 | +$45,133,345 | $28.08 | 156 |
| 2022 Q3 | 57,972,960 | $1,639,524,356 | -$46,396,034 | $28.28 | 155 |
| 2022 Q2 | 59,017,906 | $1,308,562,484 | -$21,425,021 | $22.17 | 143 |
| 2022 Q1 | 59,895,743 | $1,743,443,247 | +$19,219,573 | $29.11 | 146 |
| 2021 Q4 | 59,210,281 | $1,947,305,194 | -$73,787,635 | $32.87 | 148 |
| 2021 Q3 | 60,890,488 | $2,810,077,563 | -$244,072,957 | $46.15 | 157 |
| 2021 Q2 | 65,926,694 | $3,632,531,095 | +$51,380,893 | $55.11 | 179 |
| 2021 Q1 | 65,233,267 | $3,366,007,585 | +$56,136,770 | $51.64 | 168 |
| 2020 Q4 | 64,981,734 | $2,817,090,446 | -$19,419,372 | $43.33 | 189 |
| 2020 Q3 | 65,869,834 | $2,304,359,620 | -$101,763,130 | $35.00 | 206 |
| 2020 Q2 | 67,492,943 | $3,609,431,770 | -$76,258,753 | $53.48 | 205 |
| 2020 Q1 | 69,390,256 | $2,461,883,479 | +$6,215,421 | $35.48 | 188 |
| 2019 Q4 | 69,034,713 | $3,296,545,303 | +$348,129,625 | $47.75 | 192 |
| 2019 Q3 | 61,888,248 | $2,005,330,307 | +$38,059,098 | $32.40 | 180 |
| 2019 Q2 | 60,668,045 | $3,025,896,532 | +$157,762,312 | $49.88 | 182 |
| 2019 Q1 | 60,134,445 | $4,055,728,260 | +$162,774,480 | $67.44 | 191 |
| 2018 Q4 | 58,006,486 | $2,674,145,349 | +$50,031,635 | $46.11 | 182 |
| 2018 Q3 | 55,625,309 | $4,289,793,406 | +$92,816,537 | $77.12 | 199 |
| 2018 Q2 | 54,418,427 | $4,583,658,355 | -$33,625,899 | $84.23 | 207 |
| 2018 Q1 | 54,830,882 | $4,483,993,749 | +$716,755,603 | $81.78 | 192 |
| 2017 Q4 | 46,986,627 | $2,686,172,197 | +$50,530,934 | $57.17 | 173 |
| 2017 Q3 | 46,056,523 | $3,074,218,539 | +$17,986,293 | $66.75 | 168 |
| 2017 Q2 | 46,127,851 | $2,373,318,886 | +$325,571,290 | $51.45 | 164 |
| 2017 Q1 | 40,972,190 | $2,392,699,790 | +$240,606,903 | $58.40 | 154 |
| 2016 Q4 | 39,019,883 | $1,628,427,134 | +$42,873,951 | $41.73 | 154 |
| 2016 Q3 | 37,828,945 | $1,997,518,488 | +$255,912,326 | $52.82 | 160 |
| 2016 Q2 | 33,999,654 | $1,424,491,193 | +$19,274,497 | $41.89 | 150 |
| 2016 Q1 | 33,779,727 | $1,371,223,373 | +$17,925,029 | $40.60 | 151 |
| 2015 Q4 | 33,010,570 | $2,143,167,128 | +$96,156,802 | $64.92 | 141 |
| 2015 Q3 | 31,391,017 | $2,215,769,820 | +$82,761,834 | $70.59 | 149 |
| 2015 Q2 | 30,124,596 | $3,347,682,014 | +$244,304,306 | $111.14 | 159 |
| 2015 Q1 | 27,958,847 | $2,636,827,051 | -$36,991,648 | $94.30 | 149 |
| 2014 Q4 | 27,657,103 | $3,098,842,918 | +$394,968,566 | $112.04 | 142 |
| 2014 Q3 | 24,482,713 | $1,502,054,443 | +$81,527,891 | $61.35 | 119 |
| 2014 Q2 | 23,591,425 | $1,080,804,790 | +$140,019,435 | $45.82 | 99 |
| 2014 Q1 | 20,545,950 | $804,373,483 | +$93,802,312 | $39.15 | 73 |